Aggregation –> Chargeback Accuracy –> ROI

Last week I attended my favorite annual conference on pharma serialization and tracing in the U.S.:  The Healthcare Distribution Management Association’s (HDMA) Traceability Seminar.  They call it a “seminar” because the subject of the sessions are generally the same every year, but it is better than any other third-party conference, primarily because the right people

Looking for Serialization & Tracing Insights?

To get full access to this and other great RXTRACE_LOGO_Trans_250x94 essays, you need to
either Login, or upgrade your current subscription!
 Unlimited access is just a few clicks away!
To learn why RXTRACE_LOGO_Trans_250x94 is such a great value, click here.









3 thoughts on “Aggregation –> Chargeback Accuracy –> ROI”

  1. Agree with the near-term role of serialization for accounting for chargebacks. As discussed, serialization is also important for pharma to provide service beyond the script for high cost specialty pharma. Believe both will drive adoption sooner that required by regulation. Off to Vienna next month for a Parenteral Drug Association on smart delivery systems.

  2. Dirk,

    I’m glad the conference (seminar) was beneficial, data always goes a long way over emotion, and I agree… we need to look at this as a supply chain entity…. cost to one body needs to be offset by benefits, or drug prices will go up.

    I believe what the one gentleman presented will provide the opportunity to actually vet out these discussions with facts, and arrive at an industry compromise as the best solution.

    Crazy to think that some of us kinda overlook 2019…. but that number presented was pretty impactful.

  3. Dirk,
    Happy to see you are willing to change your position. There are other ways that wholesale operations can be streamlined through the use of manufacturer provided aggregation data. As far as chargebacks are concerned, I think you have to agree that it is a pretty convoluted process, and would not exist in its current form if the manufacturers had had a way of administering and implementing contracts at the time the process was conceived. But today is different and 2017 will be different still. We need to re-look at that process and see if it still makes sense, and if not, change it. There are a whole lot of costs that can be wrung out of the supply chain, and you are right that these need to be equitably distributed across all the supply chain participants so one player does not suffer unnecessarily. And the savings will need to find their way to the patient as well. There is, and will continue to be, enormous pressure to reduce the costs of healthcare, while improving outcomes. Its going to take a lot of work between manufacturers, wholesalers, hospitals payers and others to re-engineer the process and increase the value proposition.

Comments are closed.